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Abstract
Background: Adhesions develop in over 90% of patients after intra-abdominal surgery. Adhesion barriers are rarely
used despite the high morbidity caused by intra-abdominal adhesions. Only one of the currently available
adhesion barriers has demonstrated consistent evidence for reducing adhesions in visceral surgery. This agent has
limitations through poor handling characteristics because it is sticky on both sides. C-Qur™ Film is a novel thin film
adhesion barrier and it is sticky on only one side, resulting in better handling characteristics. The objective of this
study is to assess efficacy and safety of C-Qur™ Film to decrease the incidence of adhesions after colorectal surgery.
Methods/Design: This is a prospective, investigator initiated, randomized, double-blinded, multicenter trial. Eligible
patients undergoing colorectal resection requiring temporary loop ileostomy or loop/split colostomy by laparotomy
or hand assisted laparoscopy will be included in the trial. Before closure, patients are randomized 1:1 to either the
treatment arm (C-Qur™ Film) or control arm (no adhesion barrier). Patients will return 8 to 16 weeks post-colorectal
resection for take down of their ostomy. During ostomy takedown, adhesions will be evaluated for incidence, extent,
and severity. The primary outcome evaluation will be assessment of adhesions to the incision site. It is hypothesized that
the use of C-Qur™ Film underneath the primary incision reduces the incidence of adhesion at the incision by 30%.
To demonstrate 30% reduction in the incidence of adhesions, a sample size of 84 patients (32 + 10 per group
(25% drop out)) is required (two-sided test, α = 0.05, 80% power).
Discussion: Results of this study add to the evidence on the use of anti-adhesive barriers in open and laparoscopic
‘hand-assisted’ colorectal surgery. We chose incidence of adhesions to the incision site as primary outcome measure
since clinical outcomes such as small bowel obstruction, secondary infertility and adhesiolysis related complications are
considered multifactorial and difficult to interpret. Incidence of adhesions at repeat surgery is believed to be the most
valuable surrogate endpoint for clinically relevant adhesion prevention, since small bowel obstruction and adhesiolysis
at repeat surgery are not likely to occur when complete adhesion reduction in a patient is accomplished.
Trial registration: ClinicalTrials.gov Identifier NCT01872650, registration date 6 June 2013.
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Background
Postoperative adhesions develop in more than 90% of
patients undergoing an intra-abdominal surgical procedure
[1]. These adhesions are known to cause small bowel
obstruction, secondary infertility and pain [2-4]. At repeat
abdominal surgery, intra-abdominal adhesions necessitate
adhesiolysis, leading to increased operating times and
substantial risk of intra- and postoperative complications
[5,6]. The clinical implications of adhesions carry a signifi-
cant health and socioeconomic burden [7,8].
Adhesions are fibrous bands that connect tissue sur-
faces where anatomical connections do not normally
exist. Adhesions are formed after a tissue surface has
been injured (abrasion, desiccation, dissection, etcetera)
and the subsequent process of fibrinolysis is incomplete
[9]. At present, there are several products on the market
to combat postsurgical adhesion formation. These are
broad coverage adhesion barriers, generally consisting of
liquids, like icodextrin 4% (Adept™, Baxter, Deerfield, IL,
USA) adhesion reduction solution. These materials may
limit adhesion formation by minimizing tissue insult
during the surgical procedure when used as an intra-
operational lavage. At the conclusion of the surgical pro-
cedure, instillation of large volumes of liquid acts to
separate tissue surfaces by hydroflotation, limiting tissue-
tissue contact. Broad coverage adhesion prevention has
the distinct advantage of allowing the surgeon to treat
many areas of the intraperitoneal space at once. A dis-
advantage is the lack of control giving adhesion preven-
tion at sites at risk for complications of adhesion
prevention such as an anastomosis. In addition, side ef-
fects of abdominal distension and vulvar swelling are
commonly encountered in the use of liquids [10]. The
second group of barriers consists of local coverage ad-
hesion barriers: films, sprays, or gels that are applied
directly to adhesiogenic tissue surfaces to act as a phys-
ical barrier that blocks tissue-tissue contact. The barrier
is generally only effective when it remains at the site of
treatment. This requires the barrier to either be sutured
or glued in place or to have tissue adherent properties.
All local coverage adhesion barriers require the surgeon
to anticipate where adhesions are likely to occur and to
apply the barrier directly to those sites. These generally
include sites where the peritoneum was interrupted
during the surgical procedure, such as under a laparot-
omy incision to minimize adhesions between the inci-
sion site and the viscera [11].
Despite the frequent occurrence of adhesions after sur-
gery and the availability of different adhesion barriers,
these barriers are rarely used by general surgeons. This
discrepancy might be explained by an underestimation
of the impact of adhesions [12]. Also, of all the clinically
available adhesion barriers, only HA/CMC (hyaluronate/
carboxymethylcellulose) barrier film (Seprafilm™, Sanofi,
Paris, France) has demonstrated consistent evidence for
reducing adhesions in visceral surgery. Seprafilm™ has
limitations through poor handling characteristics be-
cause it is sticky on both sides. In a large, prospective,
randomized controlled multicenter study on the safety
of Seprafilm™, significantly more anastomotic leak and
leak-associated complications occurred in the Seprafilm™
group due to the wrapping of Seprafilm™ around an
anastomosis [13]. A subgroup analysis of control pa-
tients and patients without (593 patients) Seprafilm™
wrapped around the anastomosis showed no significant
difference. Therefore, wrapping the suture or staple line
of a fresh bowel anastomosis should be avoided.
Atrium (Atrium Medical Corporation, Maquet Gentinge
Group, Hudson, NH, USA) has developed and manufac-
tures C-Qur™ Film Adhesion Barrier, a novel thin film ad-
hesion barrier for intraperitoneal use in general surgeries.
The C-Qur™ Film has been approved for use in humans
and received a CE mark on 13 May 2011 (CE number
10123365). The evidence on efficacy and safety of the
C-Qur film originates from research on the C-Qur mesh,
a mesh with an omega-3 fatty acid coating used for pa-
tients with an abdominal ventral hernia. The C-Qur mesh
was found to be safe in intraperitoneal use and reduces
adhesions to the mesh [14]. The C-Qur™ Film falls into
the category of local coverage adhesion barriers. The
C-Qur™ Film is an adhesion barrier consisting of a non-
adhesive omega-3 fatty acid layer on one side and a Na-
CMC (sodium-carboxymethylcellulose) tissue adherent
coating on the other side. It is fully resorbable and de-
signed to adhere to the site of treatment for a time that
is sufficient to minimize postsurgical adhesion forma-
tion and clearance from the site of treatment within
approximately 60 days. In contrast to Seprafilm™, The
C-Qur™ Film is a one-sided adherent, resulting in good
handling characteristics. It offers the potential patient
benefits of reduced adhesion formation and correspond-
ing reduction of small bowel obstruction, secondary
infertility, pain and adhesiolysis at repeat surgery. The
aim of this study is to assess the efficacy and safety of
C-Qur™ Film to decrease the incidence of adhesions
after colorectal surgery.
Methods/Design
The CLIPEUS trial is registered with the ClinicalTrials.gov
Identifier NCT01872650. The protocol was ethically appro-
ved by the official Independent Review Board Nijmegen
(2013/470) and registered nationally (NL45940.091.13) [15].
Design
The CLIPEUS trial is a prospective, investigator-initiated,
randomized controlled, double-blinded, multicenter trial.
Treatment with the C-Qur™ film adhesion barrier will be
compared with no treatment with an adhesion barrier in
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patients undergoing colorectal surgery with temporary
diverting ostomy. The surgeons who have agreed to par-
ticipate in the study and perform the index procedures
will be trained in the placement of C-Qur™ Film and in
adhesion mapping.
Patients will be included at the outpatient clinics of
the participating centers (Radboud University Medical
Center, Nijmegen; Catharina Hospital, Eindhoven; Atrium
Medical Center, Heerlen; Maxima Medical Center,
Veldhoven; Gelderse Vallei Hospital, Ede) by the treating
surgeons. During the operation, when the definite decision
to create a temporary ostomy is made, patients are ran-
domized 1:1 to either the treatment arm (C-Qur™ film) or
the control arm (standard treatment: no adhesion barrier,
no placebo). In patients assigned to the treatment arm,
the C-Qur™ Film must be applied beneath the incision.
The C-Qur™ film can also be applied to other areas con-
sidered to be adhesiogenic (for example, the dissection site
and ostomy site, but not around the anastomosis). The
number of C-Qur™ Film sheets placed is limited to a max-
imum area of coverage of 774 cm2 (Table 1). Patients will
return 8 to 16 weeks post-colorectal resection to have
their diverting ostomy taken down. During the takedown,
the incidence, extent and severity of the adhesions will be
evaluated.
Patients
Patients aged 18 years or older who require open or
hand-assisted laparoscopic colonic or rectal resection for
colorectal disease with the formation of a temporary
diverting loop ileostomy or colostomy and a planned
closure within 8 to 16 weeks and who visit the out-
patient clinic at one of the participating centers will be
invited to participate in this trial.
Inclusion criteria are an incision of 6 cm or longer in
case of hand-assisted laparoscopy and signed informed
consent.
Exclusion criteria include the following: pregnancy,
patients for whom it is known prior to the initial proced-
ure that loop ileostomy or colostomy closure between 8
and 16 weeks is not feasible, active intra-abdominal
infection such as peritonitis, abdominal abscess, anasto-
motic leakage or fistula (interloop abscess in the resection
specimen is not an exclusion criterion), endometriosis,
known allergies to any component of the C-Qur Film
device, an additional procedure at the time of loop ileos-
tomy or colostomy takedown deemed interfering with
adhesion assessment by the treating surgeon, intended use
of intraoperative lavage/irrigation with any anti-adhesion
solutions other than lactated ringers and/or saline (for
example, dextran, heparin, corticosteroids, icodextrin, any
other irrigant that is believed to have anti-adhesion prop-
erties) or an adhesion barrier other than C-Qur Film™,
(planned) administration of systemic agents with the
intention to prevent adhesion formation within 30 days
prior to the index procedure, planned chemotherapy and/
or abdominal radiotherapy between index surgery and
loop ileostomy or colostomy takedown, use of immune
system suppressants deemed by the surgeon to interfere
with wound healing (patients taking daily doses of cortico-
steroids exceeding 20 mg within the prior 30 days are to
be excluded; patients requiring perioperative corticoster-
oid supplementation are not to be excluded), impaired im-
mune system function or coagulation disorders deemed
by the surgeon to interfere with wound healing, a known
history of severe multiple drug allergies, a life expectancy
of less than 6 months because of a medical condition or
disease state, a medical condition or other serious condi-
tion that will interfere with compliance and/or ability to
complete this study protocol or patients who in the opin-
ion of the investigator would not be a good candidate for
enrolment, or participation in a study of another investiga-
tional device or drug.
Intervention
All patients will undergo a colorectal resection with the
creation of a temporary loop ileostomy or loop or split
colostomy. During this index operation, adhesions, if
any, will be mapped. The incidence, location, extent and
severity and any treatment of adhesions will be noted.
For quantifying the extent of adhesions to the abdominal
wall and between organs, the abdominal wall is divided
into nine segments and the abdominal cavity into ten
segments (Figure 1). Severity of the adhesions will be
classified according to the Zühlke classification (Table 2)
[16]. Classification of operative wounds based on degree
of microbial contamination, number of serosal injuries
and number of inadvertent enterotomies will also be
noted in the source notes and CRF (case report form).
For patients randomized to the C-Qur™ Film arm, the
C-Qur™ Film must be applied to the viscera underneath
the primary or specimen retrieval incision in case of
hand-assisted laparoscopy. Preferably, the C-Qur™ Film
is also applied to other areas considered to be adhesio-
genic, such as the peritoneal dissection planes and the
ileum or colon at the ostomy site. The number of C-Qur™
Film sheets placed in the abdomen is limited to a max-
imum area of coverage of 774 cm2. In case sheets of the
largest size (15 cm× 12.5 cm) are used, the maximum is
Table 1 Maximum area of coverage and number of sheets
Code Size (cm) Maximum
Area (cm2) Number of sheets
32024 7.5 × 10.0 774 10
32025 7.5 × 12.5 774 8
32029 10.0 × 10.0 774 7
32031 12.5 × 15.0 774 4
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four sheets (Table 1). The application of C-Qur™ Film
directly to a fresh bowel anastomosis is not allowed.
Control arm
Patients who are not allocated to the treatment group
will receive standard treatment, which means no C-Qur™
Film or any other treatment considered to have anti-
adhesion properties (for example, corticosteroids, dex-
tran, heparin, icodextrin, etcetera) and no placebo will
be used.
Outcome measures
The primary outcome measure will be the incidence of
adhesions to the primary incision site or the specimen
retrieval incision in the case of hand-assisted laparoscopy.
Secondary outcome measures on effectiveness are the
extent and severity of adhesions to the primary incision
site or specimen retrieval incision, incidence, extent and
severity of adhesions at the loop ileostomy or loop/split
colostomy site and of adhesions at areas potentially
injured during the initial procedure, duration of ileostomy
or loop/split colostomy takedown from the start of the
takedown to the time the bowel is repositioned in the ab-
domen, percentage (%) of abdominal wall with adhesions,
number of C-Qur™ barrier films used, sizes of C-Qur™ bar-
rier films used, areas treated with C-Qur™ Films (under-
neath incision, ostomy bowel loops, other areas injured
during initial procedure and considered adhesiogenic),
reason for not placing film in one or more of the areas
considered to be adhesiogenic, incidence of chronic abdo-
minopelvic pain, incidence of other gastrointestinal
complaints, quality of life as assessed by Short Form-36
and DASI, and total direct health care costs (30 days-in-
hospital healthcare costs during both hospital stays).
Secondary outcome measures on safety are incidence of
postoperative complications. Complications are divided
into surgical and medical complications. Surgical compli-
cations are superficial incisional surgical site infections,
deep incisional surgical site infections, anastomotic
leakage, intra-abdominal abscess, peritonitis, unexplained
fever, fascia dehiscence, wound dehiscence, postoperative
hemorrhage, and postoperative ileus (POI). Medical com-
plications are pulmonary embolism, pneumonia, urinary
tract infection, sepsis, and death.
Other secondary outcome measures are reoperations,
number of re-laparotomies, number of inserted central
venous lines, other re-operations, first postoperative day
of oral food intake, parenteral feeding, number of days
parenteral feeding required, tube feeding, number of
days tube feeding required, first postoperative day of
passing flatus, first postoperative day of passing stool,
usage of pain medication, daily VAS (Visual Analog
a b
Figure 1 Segments of the abdominal wall and segments of the abdominal cavity. a. The nine segments of the abdominal wall; b. The ten
segments of the abdominal cavity.
Table 2 Adhesion classification system according to
Zühlke [16]
Score Observation
0 No adhesions
1 Adhesions that are filmy and easy to separate by
blunt dissection
2 Adhesions where blunt dissection is possible but
sharp dissection necessary, beginning vascularization
3 Lysis of adhesions possible by sharp dissection only,
clear vascularization
4 Lysis of adhesions possible by sharp dissection only,
organs strongly attached with severe adhesions,
damage of organs hardly preventable
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Scale) scores, hospital stay, Intensive Care Unit stay,
Recovery Unit stay, readmissions within 30 days after
discharge, and in-hospital mortality.
Randomization and blinding
Intra-operatively, the treating surgeon judges whether the
patient is eligible for definite inclusion. Prior to formation
of the temporary loop ileostomy, loop or split colostomy,
included patients will be randomized. Patients will be ran-
domized in a 1:1 fashion to the C-Qur™ Film arm (treat-
ment arm) or the control arm. The randomization will be
stratified by operative technique (open or hand-assisted
laparoscopy). The allocation sequence will be computer-
generated through the web-based program Alea©. A re-
searcher who does not participate in the data analysis
will manage the randomization process. This way, the
researcher who will perform the data analysis is blinded
from treatment allocation. Concealment of treatment
allocation and blinding of the surgeon performing the
index procedure is not possible because the patient will
either get the intervention or does not get an interven-
tion at all. Randomization will be noted in the operation
reports, allocation will not.
The patient and doctor at the surgical ward who will
complete the case report form during the post-operative
period is blinded from treatment allocation. To achieve
blinding during the data collection of outcome parame-
ters, the surgeon who will perform the ostomy takedown
procedure, will not be the same surgeon as the one who
performed the index procedure. Because of the absence
of clinical notes regarding allocation, however, the initial
surgeon is allowed to do the ostomy takedown in case of
man-power or organizational problems.
During the postoperative period after the ostomy take-
down, the physician at the ward, who will collect the
data regarding the post-operative parameters, will be
blinded from the treatment allocation of the patient.
The patient will stay blinded for the received treatment.
Unblinding protocol
A Data Safety Monitoring Board (DSMB) meeting for
safety assessment will be scheduled once every 15 patients
have been enrolled. The study will be deblinded when
there is a higher mortality rate or incidence of surgical
complications than can be expected from data found in the
literature. The deblinding will be performed by the same
researcher who performs the randomization procedure.
Patients will be informed on request about the perfor-
med procedure only after completing the quality-of-life
questionnaires 1 year postoperatively.
Data recording and follow-up
All included patients will preoperatively fill in two ques-
tionnaires on quality of life (SF-36, short-form 36, and
DASI, duke activity status index) and one questionnaire
on gastro-intestinal complaints (GIC). Preoperatively, in-
formation on the following will be collected: age, sex,
weight, height, American Society of Anesthesiologists
(ASA) classification, smoking status, Revised Cardiac
Risk Index (RCRI), chronic obstructive pulmonary dis-
ease (COPD)/asthma, diabetes mellitus, primary clinical
diagnosis, medical/surgical history, number of previous
laparotomies, type of previous laparotomies, number of
previous laparoscopies, type of previous laparoscopies,
and medication usage. A physical exam will be performed,
which includes vital signs and laboratory collection (to
include C-reactive protein (CRP), chemistry, hematology
and coagulation) and a pregnancy test if the patient is
premenopausal.
Classification of operative wounds based on the degree
of microbial contamination, the number of serosal injuries
and the number of inadvertent enterotomies will be noted
in the source notes and CRF.
The type of abdominal closure (layered or mass fascia
closure) and suture material used will be noted in the
source notes and CRF.
Patients in both groups will receive the same postopera-
tive treatment. Until patients are discharged, the following
parameters will be collected: postoperative complications
(superficial incisional surgical site infections, deep inci-
sional surgical site infections, anastomotic leakage, intra-
abdominal abscess, peritonitis, unexplained fever, fascia
dehiscence, wound dehiscence, postoperative hemorrhage,
postoperative ileus (POI), pulmonary embolism, pneu-
monia, urinary tract infection, sepsis, and death), reo-
perations, first post-operative day of oral food intake,
parenteral feeding, number of days parenteral feeding
required, tube feeding, number of days tube feeding re-
quired, first post-operative day of passing flatus, first
post-operative day of passing stool, usage of medication
including pain medication, daily VAS-scores, hospital stay,
Intensive Care Unit stay and Recovery Unit stay.
Patients will return 8 to 16 weeks after index surgery
to have their ostomy taken down. Clinical follow-up to
obtain update(s) on adverse events (AE’s), adhesion-
related events, changes in concomitant medications, the
presence/absence of surgical site infection (SSI) and the
type of SSI (if applicable) will be done during the admis-
sion for ileostomy/colostomy takedown. Weight and vital
signs will be noted and the following laboratory inves-
tigations will be repeated: CRP, sodium (Na), potassium
(K), urea, creatinine, hemoglobin, white blood cell count,
platelet count, international normalized ratio (INR) and
prothrombin time (PT).
Patients in both groups will undergo the same proced-
ure for ostomy closure. To evaluate the adhesions at the
loop ileostomy/colostomy site, the incidence, severity
and extent of adhesions around the ostomy have to be
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evaluated during takedown. The time required for take-
down of the ostomy is defined as the time from start of
the takedown to the time the bowel is repositioned in
the abdomen, and this time will be noted on the CRF.
The severity of adhesions will be scored according to the
Zühlke classification (see Table 2). To assess the extent
of adhesions, the ostomy is divided in four quadrants
(Figure 2). The extent of adhesions is scored as the num-
ber of quadrants containing adhesions (Table 3). After
the ileostomy/colostomy takedown is completed, the
surgeon will introduce a laparoscope at the ostomy site
and evaluate the incidence, extent and severity of adhe-
sions at the incision site and at other areas potentially
injured (and covered) during the initial procedure. The
severity will be scored according to the Zühlke classifica-
tion (see Table 2). The extent of adhesions underneath
the incision site will be scored through estimation of the
area covered by adhesions as a percentage of the total
area underneath the incision. The incidence and severity
of adhesions at other areas potentially injured during the
initial procedure will be scored according to the Zühlke
classification (see Table 2).
One year after randomization, patients in the treat-
ment and control arm will be approached to fill in the
same questionnaires on quality of life (SF-36 and DASI)
and gastrointestinal complaints (GIC) as preoperatively.
Ethics and informed consent
This study is conducted in concordance with the princi-
ples of the Declaration of Helsinki [17] and Good Clinical
Practice guidelines. The protocol was ethically approved
by the official Independent Review Board Nijmegen
(2013/470) and registered nationally (NL45940.091.13)
[15]. A Data and Safety Monitoring Board (DSMB) is
established to perform safety surveillance and to perform
interim analysis on the safety data, as described.
Patients will be screened in the outpatient clinic for
participation in this study by a surgeon in one of the
hospitals that will contribute to this study. Each patient
must meet the inclusion/exclusion criteria of this trial.
All potentially eligible patients are required to sign an
informed consent after careful consideration. Patients
have to sign the informed consent prior to the index
procedure.
Analysis and sample size
It is hypothesized that the use of the C-Qur™ Film
underneath the primary incision reduces the incidence
of adhesion at the incision by 30%. This hypothesis is
based on the supporting documentation for Seprafilm™
(treatment) versus Control (no treatment) with an adhe-
sion rate of 94% in the control group and 64% in the
treatment group [18-22]. We estimate a total drop out
of 25% in this study, comprising 10% regular drop out
and 15% drop out because of anastomotic leakage. A
15% drop out because of anastomotic leakages is chosen
because it is the upper limit of the incidence of this
complication. Assuming that the C-Qur™ Film group
performs similarly to Seprafilm™, a total of 84 patients,
(32 + 10 per group (25% drop out)) would be needed in
a randomized study, with 80% power and two-sided
alpha = 0.05 in order to detect a 30% reduction in inci-
dence of adhesions.
Statistics
In general, for continuous variables, the mean, standard
deviation, median, IQR, minimum and maximum values
will be presented. Groups will be compared using the
t-test or Mann-Whitney U test, as appropriate, based
on the distribution of the data. For categorical variables,
the frequencies and percentage within each category will
be calculated. Groups will be compared using the chi-
square or Fisher’s Exact test, as appropriate, based on the
expected counts. All available data will be summarized.
Demographics, preoperative, perioperative, and postopera-
tive parameters will be reported and compared for both
Figure 2 Quadrants of the ostomy site.
Table 3 Classification to score the extent of adhesions
covering the stoma
Score Observation
0 No adhesions
1 Adhesions present on up to one quadrant of the stoma circle
2 Adhesions present on two quadrants of the stoma circle
3 Adhesions present on three quadrants of the stoma circle
4 Adhesions present on all four quadrants of the stoma circle
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groups. Descriptive statistics will be presented to describe
the trial results. Missing data will be evaluated by the
investigators, and appropriate action will be undertaken.
In case of skewed baseline data between groups, results
will be corrected for this data.
Our primary analysis will focus on the effectiveness
and safety of the C-Qur film between the treatment
group and the control group. A chi-square or Fisher’s
Exact test will be performed to assess a significant
improvement in the incidence, on the Zühlke score of
adhesions underneath the incision site, underneath the
loop ileostomy or loop/split colostomy site, and for the
extent of adhesions underneath the loop ileostomy or
loop/split colostomy site as well. The extent of adhesions
underneath the incision site and the time needed for
takedown of the ileostomy or loop/split colostomy will
be compared using a t-test. To assess the safety of the
C-Qur film the total incidence of postoperative complica-
tions will be compared using a t-test or a Mann-Whitney
U test. The mortality and the incidence for each separate
complication will be compared using a chi-square or
Fisher’s Exact test.
Subgroup analysis will be performed on laparoscopic
versus open colorectal resection, and on ileostomy
versus colostomy for the incidence, extent and severity
of adhesions as described above. Since data collection of
the outcome parameters is not blinded when the same
surgeon who performed the index procedure also takes
down the ostomy, subgroup analysis will be performed
for patients with and without blinded data collection of
outcome parameters.
Reporting
The CLIPEUS trial findings will be reported in concord-
ance with the Consolidated Standards of Reporting Trials
(CONSORT) checklist [23].
Discussion
Results of this study add to the evidence on the use of
anti-adhesive barriers in open and laparoscopic ‘hand-
assisted’ colorectal surgery. Although the ultimate ob-
jective of adhesion prevention is to reduce the clinical
consequences of adhesions, we chose incidence of adhe-
sions to the incision site as primary outcome measure.
Clinical outcomes such as small bowel obstruction, sec-
ondary infertility and adhesiolysis related complications
are considered multifactorial and difficult to interpret
[24]. Incidence of adhesions at repeat surgery is believed
to be the most valuable surrogate endpoint for clinically
relevant adhesion prevention, since small bowel obstruc-
tion and adhesiolysis at repeat surgery are not likely
to occur when complete adhesion reduction in a pa-
tient is accomplished. No adhesion under the incision
site in particular will benefit patients at re-laparotomy
or re-laparoscopy. Recent evidence from our group empha-
sizes the large disease and socioeconomic burden of adhe-
sions needing lysis at subsequent abdominal surgery [5].
To be able to evaluate incidence of postoperative
adhesions, a second-look surgery model is required, also
because noninvasive methods such as cine-magnetic reson-
ance imaging (MRI) have not been validated measuring ad-
hesion reduction [25]. Colorectal resection with temporary
loop ostomy is an obvious choice, since colorectal surgery
is frequently performed and known for its relatively high
incidence of adhesion-related complications [26]. We will
include patients undergoing resection for benign or
malignant indication. Malignancy is the largest indica-
tion for colorectal resection, and since (disease-free)
survival has strongly increased, life time risk of adhesion-
related complications has increased correspondingly.
In this study, both laparoscopic and open colorectal
resections will be included. In many countries, lapa-
roscopic colorectal resection for benign and malignant
diseases has gained popularity [27]. Thus, performing
only an open colonic resection study would lower the
generalizibility of the results on adhesion prevention.
Laparoscopic technique is accompanied by less tissue
trauma. Hence, it is suggested that laparoscopic colorectal
surgery results in fewer adhesions. A recently published
population-based register study specifically addressed
readmission rate for clinically apparent adhesions after
colorectal surgery, comparing the open and laparoscopic
approach [28]. Of the total of 187,148 patients included,
11,013 (5.9%) had laparoscopic resection. With a me-
dian follow-up of 31.8 months, overall adhesion-related
readmission rate was 8.1%; 8.2% after an open approach
versus 6.3% after a laparoscopic approach (P <0.001).
An important limitation of this study was the higher
percentage of emergency operations in the open group
compared to the laparoscopic group. The most common
underlying disorder for an emergency laparotomy (that
is, peritonitis) has a higher adhesion formation propensity.
Despite the relative reduction of 23% in the re-admission
rate, it should be concluded that clinically relevant conse-
quences of adhesions are substantial also after laparoscopic
surgery. A subgroup analysis for open versus laparoscopic
resection will be conducted to control for the difference in
surgical technique and concomitant adhesion formation.
For the sake of safe and secure placement of the adhesion
barrier, only patients undergoing laparoscopic resection
with a specimen extraction incision of at least 6 cm will be
included in our study. This minimal incisional length was
chosen based on previous experience with the C-Qur™
Film. The availability of different sizes of the film and the
tissue adherence only at one site improve the placement in
narrow spaces. These characteristics provide potentially
better handling when compared to the commonly used
HA/CMC barrier film in open colorectal surgery.
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Trial status
This trial has been approved by the official Independent
Review Board Nijmegen (2013/470) [15]. Inclusion has
not started.
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